Sodium-Glucose Transporter 1

The founding member of the sodium glucose transport proteins. It is predominately expressed in the INTESTINAL MUCOSA of the SMALL INTESTINE.

Also Known As:

SGLT1 Protein; SLC5A1 Protein; Sodium-Glucose Cotransporter 1; Sodium Glucose Cotransporter 1; Sodium Glucose Transporter 1

Networked: 40 relevant articles (4 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Carrier Proteins: 12999
    - Membrane Transport Proteins: 589
  - Membrane Proteins: 10078
    - Membrane Transport Proteins: 589

Experts

1.	Hirose, Masamichi: 4 articles (10/2021 - 01/2018)
2.	Ishida, Nanae: 4 articles (10/2021 - 01/2018)
3.	Saito, Maki: 4 articles (10/2021 - 01/2018)
4.	Taira, Eiichi: 3 articles (10/2021 - 09/2018)
5.	McGuire, Darren K: 3 articles (01/2021 - 09/2018)
6.	Koepsell, Hermann: 3 articles (01/2020 - 02/2014)
7.	Nakajima, Atsushi: 2 articles (10/2021 - 01/2018)
8.	Sanbe, Atsushi: 2 articles (10/2021 - 09/2018)
9.	Sato, Sachiko: 2 articles (10/2021 - 01/2020)
10.	Barta, Bálint András: 2 articles (07/2021 - 01/2020)

Related Diseases

1.	Insulin Resistance 03/27/2022 - "Compared to the high-temperature groups, in the 0.4 mg/kg chromium-supplemented group, the insulin concentration and insulin resistance index were reduced (p < 0.05), and sodium-glucose transporter 1 expression was up-regulated in jejunum (p < 0.05). " 03/27/2022 - "In conclusion, diet supplemented with 0.4 mg/kg Cr improved performance, insulin resistance and sodium-glucose transporter 1 expression and altered gut microflora structure and secretion of gastrointestinal peptides, thus showing that supplementation with chromium is beneficial to maintain glucose homeostasis and alleviate heat stress." 11/01/2023 - "Results showed that PSP improved glucose tolerance and systemic insulin sensitivity, which coincided with decreased expression of sodium-glucose cotransporter 1 and glucose transporter 2 in the intestinal epithelium induced by an activation of the phospholipase C β2/protein kinase C signaling pathway. "
2.	Constipation 01/01/2018 - "Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial." 11/01/2019 - "The new approaches to therapy include ion exchangers/transporters for functional constipation (sodium-glucose cotransporter 1, Na+/H+ exchanger 3, and solute carrier family 26 member 3 inhibitors), bile acid modulators for constipation such as ileal bile acid transporter inhibitors and fibroblast growth factor 19 analog for functional constipation, and bile acid sequestrants or farnesoid X receptor agonists for functional diarrhea. "
3.	Hyperglycemia 11/01/2017 - "Duodenal Sodium/Glucose Cotransporter 1 Expression Under Fasting Conditions Is Associated With Postload Hyperglycemia." 12/01/2009 - "Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice." 07/01/1997 - "In contrast, acarbose did not affect the transport rate of free D-fructose and did not inhibit 3-O-MG uptake in oocytes expressing sodium-glucose cotransporter 1. The findings indicate that alpha-D-glucosidase inhibitors act specifically on the entry of free glucose into the enterocyte, an additional means by which they can reduce postprandial hyperglycemia."
4.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/01/2018 - "To identify and evaluate the recent trials of sodium-glucose cotransporter 1 and 2 (SGLT1 and SGLT2, respectively) inhibitor use in patients with type 1 diabetes (T1D). " 09/01/2018 - "The objective of this study was to evaluate the efficacy and safety of the dual sodium-glucose cotransporter 1 and 2 inhibitor sotagliflozin compared with placebo when combined with optimized insulin in adults with type 1 diabetes (T1D). " 09/01/2018 - "Evaluate the efficacy and safety of the dual sodium-glucose cotransporter 1 (SGLT1) and SGLT2 inhibitor sotagliflozin in combination with optimized insulin in type 1 diabetes (T1D). "
5.	Obesity 03/01/2009 - "The intestinal sodium-glucose cotransporter 1 (SGLT1) is responsible for all secondary active transport of dietary glucose, and it presents a potential therapeutic target for obesity and diabetes. " 01/01/2023 - "Obesity and overweight are linked to increased sodium-glucose cotransporter 1 and glucose transporter 5 levels in duodenum." 01/01/2020 - "The aim of this study was to explore the dose response of licogliflozin, a dual inhibitor of sodium/glucose cotransporter 1 (SGLT1) and 2 (SGLT2), by evaluating change in body weight in adults with overweight or obesity. " 01/01/2023 - "This cross-sectional study evaluated whether those with overweight or obesity display higher duodenal protein levels of the glucose carriers sodium-glucose cotransporter 1 (SGLT-1), glucose transporter 2 (GLUT-2), and glucose transporter 5 (GLUT-5). "

Related Drugs and Biologics

1.	Glucose (Dextrose)
2.	mizagliflozin
3.	Facilitative Glucose Transport Proteins (Glucose Transporter)
4.	Incretins
5.	Protein Kinase C
6.	Type C Phospholipases
7.	Peptides (Polypeptides)
8.	Chromium
9.	Insulin (Novolin)
10.	(2S,3R,4R,5S,6R)- 2- (4- chloro- 3- (4- ethoxybenzyl)phenyl)- 6- (methylthio)tetrahydro- 2H- pyran- 3,4,5- triol

Related Therapies and Procedures

1.	Therapeutics